P
Payal Kapur
Researcher at University of Texas Southwestern Medical Center
Publications - 244
Citations - 11224
Payal Kapur is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Clear cell renal cell carcinoma & Cancer. The author has an hindex of 42, co-authored 223 publications receiving 8743 citations. Previous affiliations of Payal Kapur include University of Texas at Dallas & University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
300 correlation of loss of dab2ip gene expression with different subtypes of renal cell carcinoma and its mechanism of action
TL;DR: It is suggested that type I cytokine induces IL-6 secretion and SOCS3 expression in RCC cells, which leads to ERK phosphorylation and cell proliferation, which is possible targets for RCC treatment.
Journal ArticleDOI
HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans.
Yuanqing Ma,Allison Joyce,Olivia Brandenburg,Faeze Saatchi,Christina Stevens,Vanina Tcheuyap,Alana Christie,Quyen N. Do,Oluwatomilade Fatunde,Alyssa Macchiaroli,So C. Wong,Layton Woolford,Qurratulain Yousuf,Jeffrey Miyata,Deyssy Carrillo,Oreoluwa Onabolu,Tiffani McKenzie,Akhilesh Mishra,Tanner Hardy,Wei He,Dan Li,Alex Ivanishev,Qing Zhang,Ivan Pedrosa,Payal Kapur,Thomas Schluep,Steven B. Kanner,J. Hamilton,James Brugarolas +28 more
TL;DR: These studies provide a proof-of-principle of HIF2α inhibition by RNA-targeting drugs in ccRCC and establish a paradigm for tumor-directed RNA-based therapeutics in cancer.
Proceedings ArticleDOI
Auto-fluorescence lifetime spectroscopy for prostate cancer detection: an optical biopsy approach
TL;DR: The use of auto-fluorescence lifetime as a biomarker for prostate cancer diagnosis is reported and significant differences in cancer and benign tissue were identified.
Journal ArticleDOI
Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment
Lei Liu,Regan Schuetze,Jeni Gerberich,Ramona Lopez,Samuel O. Odutola,Rajendra P. Tanpure,Amanda K. Charlton-Sevcik,Justin K. Tidmore,Emily A.-S. Taylor,Payal Kapur,Hans J. Hammers,Mary Lynn Trawick,Kevin G. Pinney,Ralph P. Mason +13 more
TL;DR: Effective vascular disruption at doses comparable to the most effective vascular-disrupting agents (VDAs) is demonstrated, suggesting opportunities for further development.
Journal ArticleDOI
Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.
Anna Savelyeva,Feng Wang,Lei Guo,John T. Lafin,Liwei Jia,Kirill E. Medvedev,Cheryl M. Lewis,Payal Kapur,Vitaly Margulis,Solomon L. Woldu,Xiaosong Meng,Nick V. Grishin,James F. Amatruda,Lin Xu,Aditya Bagrodia +14 more
TL;DR: Metastatic teratoma in the cohort is characterized by low tumor mutational burden, recurring copy number changes, and lack of recurring SNVs, which may inform disease biology and treatment.